tiprankstipranks
Advertisement
Advertisement

RemeGen Commits US$70 Million of Idle Funds to OCBC Structured Deposit

Story Highlights
  • RemeGen is allocating part of its idle funds into a US$70 million OCBC structured deposit, under a broader RMB2.5 billion cash management mandate.
  • The medium-risk, non-guaranteed product triggers discloseable transaction rules and reflects RemeGen’s drive to optimize treasury returns within regulated risk limits.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
RemeGen Commits US$70 Million of Idle Funds to OCBC Structured Deposit

Meet Samuel – Your Personal Investing Prophet

RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.

RemeGen Co., Ltd. has authorized the use of up to RMB2.5 billion in idle self-owned funds for cash management and, under this mandate, has agreed to purchase a US$70 million profit-linked structured deposit from OCBC. The medium-risk, non-principal-guaranteed product, linked to USD bond notes and invested in standardized fixed-income assets, runs from May 2026 to May 2027, and its size triggers discloseable transaction reporting requirements under Hong Kong listing rules, underscoring the company’s active treasury management and regulatory compliance.

The OCBC “Zeng Li” series product features a floating, market-dependent yield, early redemption options subject to OCBC’s consent, and an early termination right for the bank, giving both parties flexibility in managing risk and liquidity. For RemeGen, the move reflects an effort to enhance returns on surplus cash while staying within defined risk parameters, which may support its financial stability and investment capacity without directly affecting its core biopharmaceutical operations.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates in the biopharmaceutical sector, developing and commercializing innovative therapies, and manages its financial resources through the use of wealth management products to optimize returns on idle funds.

Average Trading Volume: 4,162,412

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$69.16B

For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1